Fri, Oct 31, 2014, 2:16 AM EDT - U.S. Markets open in 7 hrs 14 mins

Recent

% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board

codyoot 141 posts  |  Last Activity: May 2, 2014 11:22 AM Member since: Oct 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    New Sequencer Line Coming!!!

    by investments2bn Apr 3, 2014 10:35 AM
    codyoot codyoot Apr 3, 2014 1:11 PM Flag

    Great find! thanks. PacBio Blog, WEDNESDAY, APRIL 2, 2014, FDA-Supported Pathogen Database to Expand with SMRT Sequencing. We’re delighted to report that Single Molecule, Real-Time (SMRT®) Sequencing will be a crucial technology in a new research program conducted by the University of Maryland School of Medicine. The Institute for Genome Sciences at the university’s medical school was awarded a contract from the FDA to sequence bacterial pathogens and contribute annotated assemblies to a database accessible through NCBI. Sequencing efforts will be performed by the Genomics Resource Center (GRC) at the institute.

    The goal of the program is to help develop a reliable database containing the genome sequences of pathogens and other microbes, providing users a comprehensive source for microbial identification. The data will also be useful for sequencing-based diagnostics aiming to identify pathogens in vitro.

    The GRC is a natural fit for the program, having sequenced more than 5,000 microbial genomes in the last five years. For more on GRC’s great track record of genome sequencing, check out our profile of the core facility.

    “This database will be an important reference for the scientific and medical diagnostic communities,” stated Claire Fraser, Director of the Institute for Genome Sciences. “We have worked with federal agencies and global scientific partners to sequence and analyze an extensive population of bacterial pathogens since our Institute launched in 2007 and are pleased to develop this reference database with the FDA.”

    PacBio will be showcasing our rapid, affordable pipeline for de novo microbial genome sequence and assembly at the upcoming American Society for Microbiology annual conference in May — stop by and see us in booth #1034.

  • Reply to

    Monday's buying opportunity

    by righttimehunter Mar 30, 2014 7:47 AM
    codyoot codyoot Apr 1, 2014 11:24 AM Flag

    pacbio is composed of just SMRT cells, a camera and a laser source. compare to other sequencers, minimal fluid handling/washing steps is required. so it should be quite easy for them to scale it down. The current bulky pacbio RS definitely has lots, lots of room for engineering improvement.

  • Reply to

    Stock being manipulated

    by rsjrds Mar 28, 2014 2:26 PM
    codyoot codyoot Mar 28, 2014 3:37 PM Flag

    to what level? chart shows IBB has increased by 242% in 5 years.

  • pacb is planning to use it first in the field of diagnostic cancer genomics, then HLA typing. it will also be very useful for microbial sequencing, both for academic research and for infectious disease outbreak surveillance.

  • google, samsung and sony all have invested in this field, they might also be interested in acquiring PACB?

  • Reply to

    130 in two weeks

    by sasihumner Jan 14, 2014 9:58 AM
    codyoot codyoot Mar 28, 2014 1:13 PM Flag

    google, samsung and sony all have invested in genomic medicine, they might also be interested?

  • codyoot codyoot Mar 28, 2014 1:06 PM Flag

    pacbio is simple as a smrt cell plus a camera. they should be able to roll out the bench top model very soon.

  • codyoot codyoot Mar 26, 2014 10:07 AM Flag

    for more detailed info on this, go to twitter and search for pacbio

  • Scientists from Frederick National Laboratory for Cancer Research and pacbio have developed and validated an amplification-free method for generating DNA sequencing libraries from very low amounts of input DNA, in the scale of 1000-fold less starting material. potential application: needle biopsy material, forensic
    or ChIP-seq samples, microorganisms refractory to growth in synthetic media, or when searching
    for rare sequence variants in unamplified nucleic acid samples, rapid identification of infectious disease
    agents.

  • Reply to

    Insider buying at 6.15 on 03/18/2014

    by rekhaus Mar 21, 2014 6:36 PM
    codyoot codyoot Mar 22, 2014 5:38 PM Flag

    both of them take $1 salary for 2013. I have no problem with this option award.

  • Reply to

    Reason for drop?

    by laonda32 Mar 21, 2014 10:39 AM
    codyoot codyoot Mar 21, 2014 12:34 PM Flag

    it's a whole biotech sector sell off, triggered by some congressmen's question on GILD Hep C drug pricing.

  • Reply to

    Recent SC 13G filing

    by codyoot Mar 11, 2014 9:22 AM
    codyoot codyoot Mar 11, 2014 10:04 AM Flag

    also, option shares awarded to employees at $7.05

  • ICS Opportunities+Millennium International Management+Israel A. Englander owns 30%, Black rock, Deerield and Maverick Capital each owns 10% of PACB shares now.

  • now they are holding 6821277 shares.

  • It's amazing to see the short interest increased from under 2 million at the beginning of the year to over 6 million now. must be very hard for them to cover on such low daily volume.

  • codyoot codyoot Nov 15, 2013 2:49 PM Flag

    besides, if nanopore is that good, Illumina wouldn't have easily given up there stake. a piece of junk, hahaha.

  • codyoot codyoot Nov 15, 2013 2:46 PM Flag

    hahaha, nanopore has never shown any kind of data except for some "squiggles" on a computer screen. I'm glad to see the nanopore drama is unfolding faster. without surprise, I would predict they will announce the delay of the so called Early access program for "technical reason" later this month.

  • Reply to

    pacb corporate info

    by codyoot Nov 15, 2013 12:27 PM
    codyoot codyoot Nov 15, 2013 12:28 PM Flag

    Our SMRT technology has the potential to impact scientific study beyond DNA sequencing. We, and our scientific collaborators, have published a number of peer-reviewed articles in journals including Science, Nature and Nature; Methods highlighting the power and potential applications of the SMRT platform. Potential commercial applications we have demonstrated include the study of chemical and structural modifications of DNA and the processing of RNA and; proteins. Our research and development efforts are focused on expanding our DNA sequencing capabilities and commercializing products based on these research findings. We believe that our SMRT platform represents a new paradigm in biological science, which we refer to as SMRT Biology, that has the potential to significantly impact a number of areas critical to humankind, including the diagnosis and treatment of disease as well as efforts to improve the world’s food and energy supply.

  • Our mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.
    We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Combining recent advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, we created a powerful technology platform called single molecule, real-time, or SMRT, technology. SMRT technology enables real-time analysis of biomolecules with single molecule resolution, which has the potential to transform our understanding of biological systems by providing a window into these systems that has not previously been open for scientific study.
    Our initial focus is on the DNA sequencing market where we have developed and introduced a novel sequencing platform, the PacBio RS II. We believe that the PacBio RS II, which uses our proprietary SMRT technology, maintains many of the key attributes of currently available sequencing technologies while solving many of the inherent limitations of previous technologies. Our system provides long readlengths, flexibility in experimental design, fast time to result and significant ease of use. The PacBio RS II consists of an instrument platform that uses our consumables including our proprietary SMRT Cell. The system is designed to be integrated into existing laboratory workflows and information systems, which should facilitate rapid adoption. Currently, our focus is on applications for clinical, basic and agricultural research, with potential uses in molecular diagnostics, drug discovery and development, food safety, forensics, biosecurity and biofuels.

PACB
6.62+0.49(+7.99%)Oct 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.